SAN DIEGO – TriLink BioTechnologies, a global provider of life science reagents and services, has announced the opening of its new cGMP mRNA manufacturing facility in San Diego.
The 32,000 square foot facility was designed specifically for mRNA manufacturing to support late-stage drug developers from Phase 2 through commercialization through TriLink’s robust mRNA manufacturing capabilities.
The facility, located in the Sorrento Valley area of San Diego, features individual Grade C clean rooms for mRNA manufacturing, increased mRNA capacity (from 1 g to over 100 g per batch), full in-house analytical services and laboratory space for on-site quality control testing. The manufacturing rooms feature state-of-the-art equipment and are ready to accommodate customers with late-stage manufacturing needs.
“This facility is expected to help move the needle on life-saving advances in mRNA therapeutics,” explained Kevin Lynch, TriLink’s Vice President and General Manager of GMP Operations.
Company and plant leadership, as well as industry guests, gathered to celebrate the opening with a ribbon cutting, an expert-led panel discussion and tours of the facility, all centered around a central theme of Building the Future of mRNA.
TriLink has reliably delivered GMP services to drug developers since the debut of its first cGMP facility in 2015. Since then, the company’s dedicated team of scientists has provided more than 1,000 customers with custom mRNA synthesis, supported more than 350 programs in biopharmaceutical development pipelines, and delivered more than 100 GMP mRNA manufacturing batches.
